Michele Thai1, Sarah Hilmer2,3, Sallie-Anne Pearson4, Emily Reeve2,3, Danijela Gnjidic5. 1. Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. mtha3748@uni.sydney.edu.au. 2. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. 3. Cognitive Decline Partnership Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia. 4. Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. 5. Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au.
Abstract
BACKGROUND: A significant proportion of older people are prescribed statins and are also exposed to polypharmacy, placing them at increased risk of statin-drug interactions. OBJECTIVE: To describe the prevalence rates of potential and clinically relevant statin-drug interactions in older inpatients according to frailty status. METHODS: A cross-sectional study of patients aged ≥65 years who were prescribed a statin and were admitted to a teaching hospital between 30 July and 10 October 2014 in Sydney, Australia, was conducted. Data on socio-demographics, comorbidities and medications were collected using a standardized questionnaire. Potential statin-drug interactions were defined if listed in the Australian Medicines Handbook and three international drug information sources: the British National Formulary, Drug Interaction Facts and Drug-Reax(®). Clinically relevant statin-drug interactions were defined as interactions with the highest severity rating in at least two of the three international drug information sources. Frailty was assessed using the Reported Edmonton Frail Scale. RESULTS: A total of 180 participants were recruited (median age 78 years, interquartile range 14), 35.0% frail and 65.0% robust. Potential statin-drug interactions were identified in 10% of participants, 12.7% of frail participants and 8.5% of robust participants. Clinically relevant statin-drug interactions were identified in 7.8% of participants, 9.5% of frail participants and 6.8% of robust participants. Depending on the drug information source used, the prevalence rates of potential and clinically relevant statin-drug interactions ranged between 14.4 and 35.6% and between 14.4 and 20.6%, respectively. CONCLUSION: In our study of frail and robust older inpatients taking statins, the overall prevalence of potential statin-drug interactions was low and varied significantly according to the drug information source used.
BACKGROUND: A significant proportion of older people are prescribed statins and are also exposed to polypharmacy, placing them at increased risk of statin-drug interactions. OBJECTIVE: To describe the prevalence rates of potential and clinically relevant statin-drug interactions in older inpatients according to frailty status. METHODS: A cross-sectional study of patients aged ≥65 years who were prescribed a statin and were admitted to a teaching hospital between 30 July and 10 October 2014 in Sydney, Australia, was conducted. Data on socio-demographics, comorbidities and medications were collected using a standardized questionnaire. Potential statin-drug interactions were defined if listed in the Australian Medicines Handbook and three international drug information sources: the British National Formulary, Drug Interaction Facts and Drug-Reax(®). Clinically relevant statin-drug interactions were defined as interactions with the highest severity rating in at least two of the three international drug information sources. Frailty was assessed using the Reported Edmonton Frail Scale. RESULTS: A total of 180 participants were recruited (median age 78 years, interquartile range 14), 35.0% frail and 65.0% robust. Potential statin-drug interactions were identified in 10% of participants, 12.7% of frail participants and 8.5% of robust participants. Clinically relevant statin-drug interactions were identified in 7.8% of participants, 9.5% of frail participants and 6.8% of robust participants. Depending on the drug information source used, the prevalence rates of potential and clinically relevant statin-drug interactions ranged between 14.4 and 35.6% and between 14.4 and 20.6%, respectively. CONCLUSION: In our study of frail and robust older inpatients taking statins, the overall prevalence of potential statin-drug interactions was low and varied significantly according to the drug information source used.
Authors: Jacob Abarca; Daniel C Malone; Edward P Armstrong; Amy J Grizzle; Philip D Hansten; Robin C Van Bergen; Richard B Lipton Journal: J Am Pharm Assoc (2003) Date: 2004 Mar-Apr
Authors: Alexander Bennett; Danijela Gnjidic; Mark Gillett; Peter Carroll; Slade Matthews; Kristina Johnell; Johan Fastbom; Sarah Hilmer Journal: Drugs Aging Date: 2014-03 Impact factor: 3.923
Authors: D Gnjidic; S N Hilmer; F M Blyth; V Naganathan; R G Cumming; D J Handelsman; A J McLachlan; D R Abernethy; E Banks; D G Le Couteur Journal: Clin Pharmacol Ther Date: 2012-02-01 Impact factor: 6.875
Authors: Tessa K Morgan; Margaret Williamson; Marie Pirotta; Kay Stewart; Stephen P Myers; Joanne Barnes Journal: Med J Aust Date: 2012-01-16 Impact factor: 7.738
Authors: Amit M Patel; Salimah Shariff; David G Bailey; David N Juurlink; Sonja Gandhi; Muhammad Mamdani; Tara Gomes; Jamie Fleet; Y Joseph Hwang; Amit X Garg Journal: Ann Intern Med Date: 2013-06-18 Impact factor: 25.391
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Carolyn T Thorpe; Florentina E Sileanu; Maria K Mor; Xinhua Zhao; Sherrie Aspinall; Mary Ersek; Sydney Springer; Joshua D Niznik; Michelle Vu; Loren J Schleiden; Walid F Gellad; Jacob Hunnicutt; Joshua M Thorpe; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2020-08-12 Impact factor: 5.562
Authors: Davide L Vetrano; Amaia Calderón-Larrañaga; Alessandra Marengoni; Graziano Onder; Jürgen M Bauer; Matteo Cesari; Luigi Ferrucci; Laura Fratiglioni Journal: J Gerontol A Biol Sci Med Sci Date: 2018-09-11 Impact factor: 6.053
Authors: Emma Ef Kleipool; Johannes An Dorresteijn; Yvo M Smulders; Frank Lj Visseren; Mike Jl Peters; Majon Muller Journal: Heart Date: 2019-11-28 Impact factor: 5.994